DETERA Therapeutics

DETERA Therapeutics is a Paris-based preclinical biotechnology company developing first-in-class, transformative therapies for severe and rare kidney diseases. Founded in 2024 as a spin-off from CEA and Inserm, the company's lead candidate is DTR8, a patented, engineered peptide/recombinant protein that acts as a potent antagonist of Heparin-Binding Epidermal Growth Factor (HB-EGF). DTR8 is designed to treat crescentic glomerulonephritis (CGN), particularly in patients with ANCA-associated vasculitis, by acting locally in the kidney to prevent glomerular degradation and halt disease progression. The company is also developing a companion diagnostic test to support its therapeutic pipeline and aims to advance its candidates through Phase II clinical trials before seeking licensing partnerships.